EXL Price sensitive 28 Feb 2025, 10:03 AM

FY24 Results Presentation

Elixinol Wellness Ltd

Elixinol Wellness Ltd FY24 Results Presentation

Key points

  • Strategic acquisitions and retail diversification drive 81% revenue growth
  • Adjusted EBITDA loss improved 40% to $2.8M, moving towards profitability
  • Gross margins rebounded to 40% in Q4 FY24 driven by operational efficiencies

Full summary

Elixinol Wellness Ltd reported a strong FY24 performance, with revenue reaching $15 million, up 80.9% from the prior year. This growth was driven by strategic acquisitions, including THC and Ananda Foods, as well as organic growth and retail diversification. The company's D2C strategy was also boosted by the acquisition of Healthy Chef, which is expected to drive further growth in FY25 with 6 new product launches planned. The group's gross margin peaked at 40% in Q4 FY24, reflecting operational efficiencies and product mix optimisation. Adjusted EBITDA loss improved by 40% to $2.8 million, and the company's after-tax loss was reduced to $1.7 million, a significant turnaround from the $7.5 million loss in the prior year. The use of $3.6 million in deferred tax assets signals the board's confidence in the company's future profitability. Elixinol USA delivered positive EBITDA in FY24, reversing the $1.3 million loss in the prior year. The company ended FY24 with $1.1 million in cash and a solid short-term funding position, extending its financial runway beyond five quarters. Looking ahead, Elixinol Wellness is focused on operational excellence, sustained expansion, and profitability, with plans to launch new products, enhance its e-commerce and pharmacy distribution, and drive further cost efficiencies.

Guidance

Elixinol Wellness is targeting profitability in FY25, with a focus on driving EBITDA growth through cost efficiencies and operational optimisation.

Outlook

In FY25, Elixinol Wellness plans to launch new products in healthy snacking and supplements, enhance product differentiation with premium, nutrient-rich formulations, and pursue strategic export opportunities. The company will also focus on streamlining operations, optimising the supply chain, and driving EBITDA growth through cost efficiencies.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in